<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01035502</url>
  </required_header>
  <id_info>
    <org_study_id>CP4055-205</org_study_id>
    <nct_id>NCT01035502</nct_id>
  </id_info>
  <brief_title>A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia</brief_title>
  <official_title>A Phase II Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clavis Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Theradex</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>INC Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clavis Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the biological activity of elacytarabine in
      combination with idarubicin in patients with acute myeloid leukaemia who has failed the first
      course of a remission-induction treatment with cytarabine (ara-C). In addition, the
      correlation between hENT1 (human equilibrative nucleoside transporter 1) and overall survival
      will be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elacytarabine (CP-4055) is a pro-drug of ara-C currently used in the treatment of patients
      with acute myeloid leukaemia. Patients with nucleoside transporter deficiency (hENT1) seem to
      have less benefit from cytarabine compared to those with a high expression of the
      transporter. Preclinical studies indicate that elacytarabine is independent of this
      transporter. Therefore, patients with low expression of hENT1 and treated with elacytarabine
      are anticipated to have a better outcome compared to patients treated with ara-C. The main
      objective of this study is to assess the biological activity of elacytarabine in combination
      with idarubicin in patients with acute myeloid leukaemia. In addition, the correlation
      between hENT1 (human equilibrative nucleoside transporter 1) and overall survival will be
      studied. Patients will be treated with elacytarabine plus idarubicin independent of their
      hENT1 status. Determination of the patients' hENT1 expression level will be done
      retrospectively. This study will also explore the safety profile of elacytarabine in
      combination with idarubicin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the rate of complete remission (CR), including complete remission with incomplete blood count recovery (CRi) in patients with AML who have not attained blast clearance after the first course of a ara-C based remission-induction therapy.</measure>
    <time_frame>Day 21 in each course</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Obtain indication on the independence between hENT1 expression level and CR or CRi. Obtain guidance on disease free survival (DFS). Obtain guidance on event free survival (EFS). Characterize the safety profile of elacytarabine plus idarubicin.</measure>
    <time_frame>Day 21 in each course</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of disease free survival (DFS), defined as time from CR + CRi to relapse</measure>
    <time_frame>Study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of event free survival (EFS), defined as time from day one of therapy until relapse or death from any cause</measure>
    <time_frame>Study end</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the safety profile of elacytarabine plus idarubicin in this patient population</measure>
    <time_frame>Study end</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Elacytarabine plus idarubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elacytarabine plus idarubicin</intervention_name>
    <description>Elacytarabine 1000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.
Idarubicin will be administered IV at a fixed dose of 12 mg/ m2/d IV on d 1-3 q3w.
It is intended that patients receive remission-induction treatment either as two combination courses, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d or one combination course, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d followed by one course elacytarabine 2000 mg/m2/d single therapy.</description>
    <arm_group_label>Elacytarabine plus idarubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a confirmed diagnosis of AML according to WHO classification (excluding
             acute promyelocytic leukaemia)

          2. Patients who have received one previous standard dose ara-C-containing regimen aiming
             at induction of complete remission (CR) and who have more than 5 % remaining blast
             cells in bone marrow following the first course of remission-induction or by other
             means documented residual disease (i.e. circulating blasts, persistent chloromas,
             other evident disease from day 12 on).

          3. Patients from whom samples for determination of hENT1 status on leukemic blast cells
             can be taken and prepared at diagnosis and/or at baseline

          4. Patients must be 18 years of age or older

          5. Patients must have ECOG performance status (PS) of 0 - 2

          6. Left ventricular ejection fraction (LVEF) must be &gt;= 45 % as measured by MUGA scan or
             2D ECHO within 14 days prior to start of therapy.

          7. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically
             sterile) must have a negative serum or urine pregnancy test within 2 weeks prior to
             beginning treatment on this study

          8. Male and female patients must use acceptable contraceptive methods for the duration of
             time on study, and males also for 3 months after the last elacytarabine dose

          9. Patients must be capable of understanding and complying with parameters as outlined in
             the protocol, and able and willing to sign a written informed consent form

         10. Patients must have the following clinical laboratory values:

               -  Serum creatinine &lt;= 1.5 x the institutional upper limit of normal (ULN)

               -  Total bilirubin &lt;= 1.5 x the ULN according to national prescribing information
                  unless considered due to Gilbert's syndrome

               -  Alanine aminotransferase (ALT) (SGPT), or aspartate aminotransferase (AST) (SGOT)
                  &lt;= 2.5 x the ULN unless considered due to organ leukemic involvement

         11. Patients must be eligible for administration of idarubicin according to current
             national prescribing information for idarubicin

        Exclusion Criteria:

          1. A history of allergic reactions to egg, idarubicin and/or other anthracyclines or
             other components of the products. A history of allergic reactions to ara-C of CTCAE
             grade 3 or 4

          2. Persistent clinically significant and relevant toxicities from the previous course of
             chemotherapy

          3. A cancer history, that according to the investigator might confound the assessment of
             the study endpoints

          4. Patients with prior treatment with a cumulative dose of doxorubicin or equivalent
             exceeding 300 mg/m2 according to the following calculation index: X/300 + Y/160 &lt; 1
             where X is the doxorubicin or equivalent dose in mg/m2 and Y is the mitoxantrone dose
             in mg/m2. These calculations are to be used as guidance as there is no maximum
             cumulative dose defined in the summary of product characteristics (SPC) for
             idarubicin. The patient should tolerate minimum one course of combination therapy

          5. Active heart disease including myocardial infarction within the previous 3 months,
             symptomatic coronary disease, arrhythmias not controlled by medication, or
             uncontrolled congestive heart failure. Any NYHA grade 3 or 4

          6. Known positive status for human immunodeficiency virus (HIV)

          7. Pregnant and nursing patients are excluded because the effects of elacytarabine on a
             fetus or a nursing child are unknown

          8. Uncontrolled intercurrent illness including, but not limited to uncontrolled
             infection, or psychiatric illness/social situations that may reduce compliance with
             study requirements

          9. Patients receiving hydroxyurea within the last 12 hours prior to treatment on this
             protocol or any other investigational or standard cytotoxic treatment within the last
             14 days, except the first remission-induction course

         10. Any medical condition, which in the opinion of the investigator places the patient at
             an unacceptably high risk for toxicities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Rizzieri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Medical Center, Durham, NC, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon, Hospital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse, Hospital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite University Hospital Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit채tsklinikum M체nster</name>
      <address>
        <city>M체nster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit채tsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>D-89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2009</study_first_submitted>
  <study_first_submitted_qc>December 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2009</study_first_posted>
  <disposition_first_submitted>September 12, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>September 12, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 18, 2013</disposition_first_posted>
  <last_update_submitted>September 20, 2013</last_update_submitted>
  <last_update_submitted_qc>September 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>CP-4055</keyword>
  <keyword>elacytarabine</keyword>
  <keyword>combination</keyword>
  <keyword>idarubicin</keyword>
  <keyword>Acute myeloid leukaemia (AML)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

